Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.
Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.
复制标题
DOI：
10.3390/cancers13174460
复制
发表时间：
2021-09-04
期刊：
影响因子：
5.2
通讯作者：
Crescioli S
中科院分区：
文献类型：
--
作者：
McCraw AJ;Chauhan J;Bax HJ;Stavraka C;Osborn G;Grandits M;López-Abente J;Josephs DH;Spicer J;Wagner GK;Karagiannis SN;Chenoweth A;Crescioli S
AllergoOncology 领域的不断发展表明了 IgE 在癌症免疫治疗中的应用潜力；然而，这一领域仍有很多值得探索的地方，特别是围绕 IgE、过敏和癌症之间的联系。探索这些联系可能会为指导基于 IgE 的新型癌症治疗策略提供有用的见解。在这里，我们总结了IgE在癌症流行病学和肿瘤免疫监测方面的现有数据，从而提出了一个新的假设，即组合假设，该假设试图概括IgE相关免疫反应与癌症之间关系的复杂性；我们讨论这些见解如何塑造下一代基于 IgE 的疗法。 IgE 是过敏反应的主要抗体类别，因其在预防寄生虫方面的作用而闻名。然而，越来越多的证据表明 IgE 及其相关效应细胞在肿瘤免疫监视中发挥着重要作用，AllergoOncology 领域和一流的 IgE 癌症治疗 MOv18 的成功凸显了这一点。大量流行病学数据支持了这一观点，认为 IgE、过敏和特应性在预防特定肿瘤类型方面具有潜在作用，并且与 IgE 免疫缺陷相关的癌症风险相应增加。在这里，我们考虑流行病学数据与功能数据相结合如何揭示 IgE 和过敏与癌症之间复杂的相互作用，而这种相互作用不能仅用现有的传统假设之一来解释。我们还进一步讨论了如何使用这些数据来指导未来的治疗方法，包括不同患者群体的临床管理。流行病学研究结果强调了高 IgE 水平可预防多种高风险癌症类型，因此使用基于 IgE 的疗法治疗一系列恶性适应症可能会提供疗效，以补充已建立的 IgG 类抗体的疗效。
The growing field of AllergoOncology has illustrated potential for the use of IgE in cancer immunotherapy; however, there is still much to be explored within this field, particularly surrounding the links between IgE, allergy, and cancer. Exploring such links may provide useful insights to guide novel IgE-based strategies targeting cancer. Here, we summarise the existing data on both IgE in cancer epidemiology and tumour immunosurveillance, leading to the proposal of a new hypothesis, the combinatorial hypothesis, which attempts to encapsulate the complexity of the relationship between IgE-associated immune responses with cancer; and we discuss how these insights may shape the next generation of IgE-based therapeutics. IgE, the predominant antibody class of the allergic response, is known for its roles in protecting against parasites; however, a growing body of evidence indicates a significant role for IgE and its associated effector cells in tumour immunosurveillance, highlighted by the field of AllergoOncology and the successes of the first-in-class IgE cancer therapeutic MOv18. Supporting this concept, substantial epidemiological data ascribe potential roles for IgE, allergy, and atopy in protecting against specific tumour types, with a corresponding increased cancer risk associated with IgE immunodeficiency. Here, we consider how epidemiological data in combination with functional data reveals a complex interplay of IgE and allergy with cancer, which cannot be explained solely by one of the existing conventional hypotheses. We furthermore discuss how, in turn, such data may be used to inform future therapeutic approaches, including the clinical management of different patient groups. With epidemiological findings highlighting several high-risk cancer types protected against by high IgE levels, it is possible that use of IgE-based therapeutics for a range of malignant indications may offer efficacy to complement that of established IgG-class antibodies.
登录
查看更多内容
影响因子：
30.5
作者：
Crawford G;Hayes MD;Seoane RC;Ward S;Dalessandri T;Lai C;Healy E;Kipling D;Proby C;Moyes C;Green K;Best K;Haniffa M;Botto M;Dunn-Walters D;Strid J
通讯作者：
Strid J
影响因子：
2.4
作者：
Bosetti, C;Talamini, R;La Vecchia, C
通讯作者：
La Vecchia, C
影响因子：
0.1
作者：
Coulson, A.;Levy, A.;Gossell-Williams, M.
通讯作者：
Gossell-Williams, M.
影响因子：
3.8
作者：
Daniels-Wells, Tracy R.;Helguera, Gustavo;Penichet, Manuel L.
通讯作者：
Penichet, Manuel L.
影响因子：
64.5
作者：
DiLillo DJ;Ravetch JV
通讯作者：
Ravetch JV